The species Bifidobacterium longum includes three subspecies, longum, infantis, and suis; the latter isolated from the pig intestine. Several strains from the subspecies infantis and longum have been isolated from the infant and adult intestine of man and developed as probiotics for use in children and adults. Laboratory studies have identified a number of properties that could be clinically relevant: immune modulation, epithelial adherence, and enhancement of gut barrier function. Several commercially available strains have been studied: B. longum bb536; B. longum es 1; B. longum w11; B. longum NCC 3001; B. longum 1714; B. longum KACC 91563; B. longum spp. longum SPM 1205, 1206, 1207, CECT 7347, MM-2; B. longum subsp. infantis ATCC 15697. In man antiinflammatory effects have been demonstrated in a number of contexts and clinical benefits demonstrated in constipation, ulcerative colitis, constipation, and celiac disease.

Original languageEnglish (US)
Title of host publicationThe Microbiota in Gastrointestinal Pathophysiology
Subtitle of host publicationImplications for Human Health, Prebiotics, Probiotics, and Dysbiosis
PublisherElsevier Inc.
Number of pages3
ISBN (Electronic)9780128040621
ISBN (Print)9780128040249
StatePublished - Nov 30 2016


  • 1206 and 1207
  • B. longum 1714
  • B. longum bb536
  • B. longum es 1
  • B. longum KACC 91563
  • B. longum NCC 3001
  • B. longum spp. longum SPM 1205
  • B. longum subsp. infantis ATCC 15697
  • B. longum w11
  • CECT 7347
  • Celiac disease
  • Constipation
  • Immune response
  • MM-2

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Bifidobacterium longum'. Together they form a unique fingerprint.

Cite this